Guest Post – Second Circuit Rejects Manufacturer’s Plan to Share Cost of Expensive Drug with Medicare Part D Beneficiaries
Drug & Device Law
OCTOBER 10, 2022
The drug at issue is the only FDA-approved pharmaceutical treatment for ATTR-CM (although off-label use of other drugs, and organ transplant, are sometimes used as treatments). Although the drug is not a “cure,” it does “slow[] the decline in quality of life, reduces hospitalization rates, and typically helps patients live longer.”
52 
Let's personalize your content